Downloads

https://doi.org/10.53941/ijctm.2025.100003
Rikhi, R. R., & Shapiro, M. D. The Role of Risk Equations in Primary Prevention of Atherosclerotic Cardiovascular Disease. International Journal of Clinical and Translational Medicine. 2025, 1(1), 3. doi: https://doi.org/10.53941/ijctm.2025.100003
Volume 1, Issue 1, 2025
Copyright (c) 2025 by the authors.
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Review

The Role of Risk Equations in Primary Prevention of Atherosclerotic Cardiovascular Disease

Rishi Rikhi and Michael D. Shapiro *

Center for Prevention of Cardiovascular Disease, Section on Cardiovascular Medicine, Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA

* Correspondence: mdshapir@wakehealth.edu; Tel.: +1-(336)-713-7085; Fax: +1-(336)-716-9188

Received: 24 January 2025; Accepted: 11 February 2025; Published: 1 March 2025

Abstract: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death in the United States. The 2018 American Heart Association (AHA)/American College of Cardiology (ACC) blood cholesterol guideline recommends the use of the pooled cohort equations (PCE) for the assessment of 10-year ASCVD risk in participants aged 40–75 years without a history of ASCVD or diabetes, and low-density lipoprotein-cholesterol (LDL-C) ≥70 mg/dL and <190 mg/dL. Recently, AHA released the Predicting Risk of Cardiovascular Disease (CVD) EVENTs (PREVENT) risk equations that calculate both 10- and 30-year ASCVD, CVD, and heart failure (HF) risk in participants aged 30–79 years. This review provides an overview of cardiovascular risk assessment in primary prevention and performance of PREVENT compared to the PCE. PREVENT offers an enhanced approach to cardiovascular risk assessment by integrating markers of cardiovascular, kidney, and metabolic health along with social determinants of health, providing superior calibration and discrimination compared to PCE. PREVENT holds promise for refining statin eligibility and identifying individuals at risk for ASCVD. However, additional research is essential to define clinical thresholds and evaluate its potential in directing the use of emerging preventive therapies. 

Keywords:

primary prevention risk prediction atherosclerotic cardiovascular disease atherosclerosis PREVENT

References

  1. Nguyen, X.T.; Li, Y.; Gong, Y.; et al. Cardiovascular Health Score and Atherosclerotic Cardiovascular Disease in the Million Veteran Program. JAMA Netw. Open 2024, 7, e2447902. https://doi.org/10.1001/jamanetworkopen.2024.47902.
  2. Khera, R.; Valero-Elizondo, J.; Nasir, K. Financial Toxicity in Atherosclerotic Cardiovascular Disease in the United States: Current State and Future Directions. J. Am. Heart Assoc. 2020, 9, e017793. https://doi.org/10.1161/JAHA.120.017793.
  3. Shapiro, M.D.; Bhatt, D.L. “Cholesterol-Years” for ASCVD Risk Prediction and Treatment. J. Am. Coll. Cardiol. 2020, 76, 1517–1520. https://doi.org/10.1016/j.jacc.2020.08.004.
  4. Ference, B.A.; Ginsberg, H.N.; Graham, I.; et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur. Heart J. 2017, 38, 2459–2472. https://doi.org/10.1093/eurheartj/ehx144.
  5. Lloyd-Jones, D.M.; Allen, N.B.; Anderson, C.A.M.; et al. Life’s Essential 8: Updating and Enhancing the American Heart Association’s Construct of Cardiovascular Health: A Presidential Advisory From the American Heart Association. Circulation 2022, 146, e18–e43. https://doi.org/10.1161/CIR.0000000000001078.
  6. Grundy, S.M.; Stone, N.J.; Bailey, A.L.; et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019, 139, e1082–e1143. https://doi.org/10.1161/CIR.0000000000000625.
  7. Arnett, D.K.; Blumenthal, R.S.; Albert, M.A.; et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019, 140, e596–e646. https://doi.org/10.1161/CIR.0000000000000678.
  8. Khan, S.S.; Matsushita, K.; Sang, Y.; et al. Development and Validation of the American Heart Association’s PREVENT Equations. Circulation 2024, 149, 430–449. https://doi.org/10.1161/CIRCULATIONAHA.123.067626.
  9. Goff, D.C., Jr.; Lloyd-Jones, D.M.; Bennett, G.; et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014, 129, S49–S73. https://doi.org/10.1161/01.cir.0000437741.48606.98.
  10. Rikhi, R.; Shapiro, M.D. Assessment of Atherosclerotic Cardiovascular Disease Risk in Primary Prevention. J. Cardiopulm. Rehabil. Prev. 2022, 42, 397–403. https://doi.org/10.1097/HCR.0000000000000746.
  11. Sarwar, A.; Shaw, L.J.; Shapiro, M.D.; et al. Diagnostic and prognostic value of absence of coronary artery calcification. JACC Cardiovasc. Imaging 2009, 2, 675–688. https://doi.org/10.1016/j.jcmg.2008.12.031.
  12. Silverman, M.G.; Blaha, M.J.; Krumholz, H.M.; et al. Impact of coronary artery calcium on coronary heart disease events in individuals at the extremes of traditional risk factor burden: the Multi-Ethnic Study of Atherosclerosis. Eur. Heart J. 2014, 35, 2232–2241. https://doi.org/10.1093/eurheartj/eht508.
  13. Martin, S.S.; Blaha, M.J.; Blankstein, R.; et al. Dyslipidemia, coronary artery calcium, and incident atherosclerotic cardiovascular disease: implications for statin therapy from the multi-ethnic study of atherosclerosis. Circulation 2014, 129, 77–86. https://doi.org/10.1161/CIRCULATIONAHA.113.003625.
  14. Nasir, K.; Bittencourt, M.S.; Blaha, M.J.; et al. Implications of Coronary Artery Calcium Testing Among Statin Candidates According to American College of Cardiology/American Heart Association Cholesterol Management Guidelines: MESA (Multi-Ethnic Study of Atherosclerosis). J. Am. Coll. Cardiol. 2015, 66, 1657–1668. https://doi.org/10.1016/j.jacc.2015.07.066.
  15. Lloyd-Jones, D.M.; Braun, L.T.; Ndumele, C.E.; et al. Use of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of Atherosclerotic Cardiovascular Disease: A Special Report From the American Heart Association and American College of Cardiology. Circulation 2019, 139, e1162–e1177. https://doi.org/10.1161/CIR.0000000000000638.
  16. Ridker, P.M.; Cook, N.R. The Pooled Cohort Equations 3 Years On: Building a Stronger Foundation. Circulation 2016, 134, 1789–1791. https://doi.org/10.1161/CIRCULATIONAHA.116.024246.
  17. Xia, M.; An, J.; Safford, M.M.; et al. Cardiovascular Risk Associated With Social Determinants of Health at Individual and Area Levels. JAMA Netw. Open 2024, 7, e248584. https://doi.org/10.1001/jamanetworkopen.2024.8584.
  18. Anderson, T.S.; Wilson, L.M.; Sussman, J.B. Atherosclerotic Cardiovascular Disease Risk Estimates Using the Predicting Risk of Cardiovascular Disease Events Equations. JAMA Intern. Med. 2024, 184, 963–970. https://doi.org/10.1001/jamainternmed.2024.1302.
  19. Diao, J.A.; Shi, I.; Murthy, V.L.; et al. Projected Changes in Statin and Antihypertensive Therapy Eligibility With the AHA PREVENT Cardiovascular Risk Equations. JAMA 2024, 332, 989–1000. https://doi.org/10.1001/jama.2024.12537.
  20. Scheuermann, B.; Brown, A.; Colburn, T.; et al. External Validation of the American Heart Association PREVENT Cardiovascular Disease Risk Equations. JAMA Netw. Open 2024, 7, e2438311. https://doi.org/10.1001/jamanetworkopen.2024.38311.
  21. Mavromatis, L.A.; Wang, D.; Selvin, E.; et al. PREVENT Risk Score and Use of Cardioprotective Agents in Type 2 Diabetes: An Analysis of NHANES 2013 to 2020. J. Am. Heart Assoc. 2024, 13, e037456. https://doi.org/10.1161/JAHA.124.037456.